Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9488
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Abadir, E. | - |
dc.contributor.author | Othman, J. | - |
dc.contributor.author | Kwan, J. | - |
dc.contributor.author | Gottlieb, David J. | - |
dc.contributor.author | Kennedy, G. A. | - |
dc.contributor.author | Bajel, A. | - |
dc.contributor.author | Doocey, R. | - |
dc.contributor.author | Perera, T. | - |
dc.contributor.author | Watson, A. | - |
dc.contributor.author | Bardy, P. G. | - |
dc.contributor.author | Greenwood, M. | - |
dc.contributor.author | Curtis, D. J. | - |
dc.contributor.author | Tran, S. | - |
dc.contributor.author | Moore, J. | - |
dc.contributor.author | Hamad, N. | - |
dc.date.accessioned | 2024-04-23T04:29:52Z | - |
dc.date.available | 2024-04-23T04:29:52Z | - |
dc.date.issued | 2024 | - |
dc.identifier.citation | Transplantation and cellular therapy 30(3):334.e1-334.e7, 2024 | - |
dc.identifier.uri | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9488 | - |
dc.description.abstract | BACKGROUND: There is a limited body of evidence for Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-HSCT) in older patients. Previous studies have used a high proportion of bone marrow derived grafts and a variety of conditioning regimens. In Australia and New Zealand, Haplo-HCST is predominantly performed using peripheral blood (PB) with universal use of post-transplant cyclophosphamide (PTCy). OBJECTIVE: To characterize the outcomes of older recipients undergoing Haplo-HSCT for Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndromes (MDS). STUDY DESIGN: Data was collected through the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) for patients aged 65 or older receiving a PB Haplo-HSCT for AML/MDS between January 2010 and July 2020 RESULTS: A total of 44 patients were included in the analysis. The median follow-up time was 377 days. The median age was 68 (range 65-74) with a median Karnofsky Performance Status of 90. Thirty patients (68.2%) had AML while 14 (31.8%) had MDS. The median donor age was 40. The most common conditioning regimen was non-myeloablative fludarabine, cyclophosphamide and TBI (75%), the remainder of the patients received either melphalan or busulfan based regimens, the majority were reduced intensity with only 2 patients undergoing myeloablative conditioning. All patients received post-transplant cyclophosphamide and mycophenolate mofetil with the majority also receiving tacrolimus (90.5%) and the remainder receiving cyclosporin (9.5%). No patients received anti-thymocyte globulin. Neutrophil engraftment was achieved in 97.6% of patients, at a median of 18 days while platelet engraftment was achieved in 92.7% of patients at a median of 28 days. The cumulative incidences of CMV reactivation and CMV disease were 52.5% and 5.1% at 1 year. The incidence of grade 2-4 acute Graft Versus Host Disease (GVHD) was 18.2%. The incidence of chronic GVHD at 2 years was 40.7%, with extensive chronic GVHD occurring in 17.7% of patients. The incidences of relapse and non-relapse mortality (NRM) at 2 years were 8.8% and 20.7% respectively. The leading causes of death were infection (64.7%) followed by relapse (14.2%). The 2-year overall survival was 74%. Relapse free survival and GVHD free, relapse free survival at 2 years was 70% and 48%. CONCLUSION: Haplo-HSCT using a peripheral blood graft and PTCy GVHD prophylaxis demonstrates long-term disease control with acceptable rates of NRM for older patients with AML/MDS. | - |
dc.subject | Haematology | - |
dc.subject | Transplantation | - |
dc.title | Peripheral blood haploidentical allogeneic stem cell transplantation in older adults with acute myeloid leukemia and myelodysplastic syndromes demonstrates long term survival, results from the Australasian Bone Marrow Transplant Recipient Registry | - |
dc.type | Journal Article | - |
dc.identifier.doi | https://dx.doi.org/10.1016/j.jtct.2023.11.018 | - |
dc.subject.keywords | graft versus host disease | - |
dc.subject.keywords | acute myeloid leukemia | - |
dc.subject.keywords | allogeneic stem cell transplantation | - |
dc.subject.keywords | bone marrow transplantation | - |
dc.subject.keywords | cytomegalovirus infections | - |
dc.subject.keywords | leukemia, acute myeloid | - |
dc.subject.keywords | peripheral blood stem cell transplantation | - |
dc.identifier.journaltitle | Transplantation and cellular therapy | - |
dc.identifier.department | Haematology | - |
dc.contributor.wslhd | Gottlieb, David J. | - |
dc.type.studyortrial | Major Clinical Study | - |
dc.identifier.pmid | 38029962 | - |
dc.identifier.affiliation | Royal Prince Alfred Hospital, Camperdown, Australia | - |
dc.identifier.affiliation | Royal North Shore Hospital, St Leonards, Australia | - |
dc.identifier.affiliation | Westmead Hospital, Westmead, Australia | - |
dc.identifier.affiliation | Royal Brisbane and Women's Hospital, Brisbane, Australia | - |
dc.identifier.affiliation | Royal Melbourne Hospital, Parkville, Australia | - |
dc.identifier.affiliation | Auckland City Hospital, Auckland, New Zealand | - |
dc.identifier.affiliation | Wellington Blood and Cancer Centre, Wellington, New Zealand | - |
dc.identifier.affiliation | Liverpool Hospital, Sydney, Australia | - |
dc.identifier.affiliation | Royal Adelaide Hospital, Adelaide, Australia | - |
dc.identifier.affiliation | The Alfred Hospital, Melbourne, Australia | - |
dc.identifier.affiliation | The Australasian Bone Marrow Transplant Recipient Registry, Darlinghurst, Australia | - |
dc.identifier.affiliation | St Vincent's Hospital, Darlinghurst, Australia | - |
dc.identifier.facility | Blacktown | - |
dc.identifier.facility | Westmead | - |
Appears in Collections: | Blacktown Mount Druitt Hospital |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.